Mitral Regurgitation (MR) is the most common type of valvular insuffi ciency. It is estimated that approximately 5 million people in the US and over 20 million worldwide suff er from congestive heart failure, many of whom are associated with dilated ventricles and coexisting MR. Ischemic cardiomyopathy is the most common cause of heart failure in the United States. This disease is marked by diff use myocardial damage, left ventricular remodeling, and often functional ischemic MR. While surgery can be eff ective in treating MR, it is frequently associated with high operative morbidity, disease recurrence and increased mortality. Currently, potential percutaneous options for the treatment of mitral regurgitation are in diff erent stages of development either under early phases of clinical use or being pre-clinically tested. These techniques include leafl et coupling with edge-to-edge repair (EValve MitraClip, Edwards Stitch), coronary sinus reshaping (Monarch device, Carillon device, Miltralife ev3, Cardiac Dimensions, Viacor), annular plication with posterior annulus reshaping (Mitralign, Guided Delivery Systems), and left ventricular remodeling (Myocor, Ample PS3). In this article, we will discuss current options and future directions for the percutaneous treatment of mitral valve regurgitation. Palabras claves: mitral regurgitation, valvular insuffi ciency, percutaneous repair of mitral insuffi ciency.